These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 16015594

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 26. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.
    Cancer Res; 2000 Oct 01; 60(19):5522-8. PubMed ID: 11034097
    [Abstract] [Full Text] [Related]

  • 27. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
    Qi H, Fillion C, Labrie Y, Grenier J, Fournier A, Berger L, El-Alfy M, Labrie C.
    Cancer Res; 2002 Feb 01; 62(3):721-33. PubMed ID: 11830526
    [Abstract] [Full Text] [Related]

  • 28. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lòpez Beltran A.
    Hum Pathol; 2006 Sep 01; 37(9):1137-44. PubMed ID: 16938518
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M.
    J Urol; 2000 Nov 01; 164(5):1819-24. PubMed ID: 11025776
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M.
    Anticancer Res; 2006 Nov 01; 26(2B):1583-7. PubMed ID: 16619575
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
    Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A.
    Proc Natl Acad Sci U S A; 2001 Feb 27; 98(5):2658-63. PubMed ID: 11226295
    [Abstract] [Full Text] [Related]

  • 36. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 27; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 37. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.
    Eur Urol; 2007 May 27; 51(5):1259-66. PubMed ID: 16806661
    [Abstract] [Full Text] [Related]

  • 38. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
    Augustin H, Freibauer C, Bayer L, Lunglmayr G, Tschurlovich F, Kuber W, Pummer K.
    Prostate Cancer Prostatic Dis; 2006 May 27; 9(3):279-83. PubMed ID: 16702984
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K.
    Int J Urol; 2007 Aug 27; 14(8):713-8. PubMed ID: 17681061
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.